Thursday, 22 Jun 2017

You are here

Nurse-Led Patient Care in Rheumatology

Manpower in rheumatology is about to be a major problem for the next several decades: not enough trainees, a "tsunami of retiring older white rheumatologists" and an aging baby-boomer, arthritis-primed population will strain current resources and manpower.  Moreover, necessary services will not likely be available to those in need and there may be a significant maldistribution of adequate rheumatologic care.

The current edition of The Journal of Rheumatology, addresses this issue with an original discussion of nurse provided rheumatologic care. 

The article discusses the multiple roles played by rheumatology nurses, playing a role in a multidisciplinary approach to caring for those with chronic arthritis.  Who better than the nurse to also address patients’ physical function, emotional, psychological, and social needs.

The European League Against Rheumatism encourages the involvementof rheumatology nurses in identifying, assessing, and addressing psychosocial issues of patients.

Research on nurse-led rheumatology care has focused on RA and shown that, compared to rheumatologists, there were no differences in outcomes such as quality of life and knowledge, fatigue and patient perceptions.

The editorial and the referenced article on this subject should be of interests to clinical practices and academic centers who need to address future manpower needs and clinic management planning. (citation source: http://buff.ly/2rC4jH3)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Abatacept for Pediatric Use

Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb.  Orencia was previously approved for use in adults with rheumatoid arthritis (RA) and was FDA approved for pediatric use in March 2017.

Both Undertreatment and Overtreatment Common in JIA

Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."

Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis

Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.  Thus while it is assumed that aberrant NLRP3 inflammasome activity underlies active AOSD, the connection between NLRP3 AOSD has yet to be solidfied.

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibotor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Although approved in Canada in February 2017, the US submission of the sarilumabs BLA was held up by the FDA with a complete response letter and concerns about manufacturing.